This month, The Fass Lane discusses the results of a study assessing the difference between potassium-competitive acid blockers and proton pump inhibitors with respect to short-term adverse events.

The FDA has approved lirafugratinib (Lyrfigtu, Elevar) for the treatment of adults with previously treated unresectable, locally advanced, or metastatic cholangiocarcinoma harboring a fibroblast ...

In this installment of our video series Through the Scope, Rajesh Keswani, MD, MS, demonstrates the importance of careful ...

Being diagnosed with inflammatory bowel disease often leads to isolation, shame, and a lot of potentially embarrassing questions.

Higher preoperative abundance of the periodontal pathogenic bacterium Porphyromonas was associated with an increased risk for recurrence in patients with early-stage colorectal cancer undergoing ...

Two leaders at the forefront of fellowship curriculum design met with GEN recently to discuss the pros and cons shortening ...

The first part of this series explained how the American healthcare system developed, and the second part starts with the result of that history: a patchwork insurance system as opposed to a single ...

These email addresses will only be used to send out this message.

Patients with celiac disease had a nearly threefold higher risk for solid organ transplantation in a recent population-based study conducted in Sweden. A link to this article will be included in this ...

Jason B. Samarasena, MD, described outcomes of colonoscopies performed with a novel robotic colonoscopy system, which was evaluated in a first-in-human study in Poland. A link to this article will be ...

A survey is an open-book test. There should not be any surprises as far as what we’re looking at, what we’re looking for, or what our approach is going to be. Joint Commission uses a tracer ...